记者从北京市科委、中关村管委会了解到，北京生物医药保险共保体于近日正式成立，这是继全国首个商业航天保险共保体落地之后，北京在科技保险领域的又一重要实践。据介绍，在该共保体成立之际，首单投保已经完成，多家意向企业投保协议也将于近期陆续落地。
生物医药行业研发周期长、投入规模大、不确定性突出，长期以来是制约创新药械企业发展、影响社会资本投入的突出痛点。其中，针对药物临床前研究以及Ⅰ、Ⅱ、Ⅲ期临床试验、NDA申报等关键阶段，目前仍面临研发损失保障供给不足的问题，相关保险存在条款适配难、赔付标准不易标准化等落地堵点。
北京生物医药保险共保体的成立，将有效分散创新药械初创企业研发风险，也为投资机构分担投资不确定性，进一步引导更多社会风险资本投向创新药械管线的临床研究环节，打通金融支持生物医药成果转化的关键环节。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.